For patients with favorable-risk AML, such as those with CBF-AML or NPM1 mutations without high allelic burden FLT3-ITD mutations, consolidative therapy often involves high-dose cytarabine to reduce the risk of relapse and improve outcomes [5,6]. Here, NPM1 is linked to acute myeloid leukemia.